Treatment options after virological failure of first-line tenofovir-based regimens in South Africa: an analysis by deep sequencing

AIDS. 2016 Apr 24;30(7):1137-40. doi: 10.1097/QAD.0000000000001033.

Abstract

In a South African cohort of participants living with HIV developing virological failure on first-line tenofovir disoproxyl fumarate (TDF)-based regimens, at least 70% of participants demonstrated TDF resistance according to combined Sanger and MiSeq genotyping. Sanger sequencing missed the K65R mutation in 30% of samples. Unless HIV genotyping is available to closely monitor epidemiological HIV resistance to TDF, its efficacy as second-line therapy will be greatly compromised.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Anti-HIV Agents / pharmacology
  • Anti-HIV Agents / therapeutic use*
  • Antiretroviral Therapy, Highly Active / methods
  • Drug Resistance, Viral*
  • Genotype
  • Genotyping Techniques
  • HIV / classification
  • HIV / drug effects*
  • HIV / genetics
  • HIV / isolation & purification
  • HIV Infections / drug therapy*
  • HIV Infections / virology*
  • High-Throughput Nucleotide Sequencing*
  • Humans
  • Microbial Sensitivity Tests
  • South Africa
  • Tenofovir / pharmacology
  • Tenofovir / therapeutic use*
  • Treatment Failure

Substances

  • Anti-HIV Agents
  • Tenofovir